Meet our team
Our team is comprised of scientists and industry leaders who are not only experts at their craft, but are creatives who think outside the box. Together with our world-class scientific advisors, we are both driven and well-positioned to overcome the hurdles ahead of us to bring impactful new therapies to patients in need.
Jem Atillasoy
Interim-CEO & President
Jem Atillasoy is a 4th year medical student at
Yale University with prior experience in life
science consulting, focusing on strategy &
business development. Previously, worked in
early clinical development at Biohaven and in
target validation at GSK.
Nicholas Economos, MD, PhD
Interim-Chief Scientific Officer
Nicholas Economos is a first year internal
medicine resident at Brigham and Women’s
Hospital. He previously completed his MD/
PhD at Yale University with 10+ years
experience investigating nucleic acid biology
and gene editing technologies.
Peter Glazer, MD, PHD
Chief Scientific Advisor, Chair of SAB
Peter Glazer is Robert E. Hunter Professor and
Chairman of Therapeutic Radiology, and
Professor of Genetics at Yale University. As a
physician-scientist Dr. Glazer has spun out
multiple successful companies. He is currently
co-founder and advisor to Cybrexa
Therapeutics and Gennao Bio.